Shandong Provincial Medicine and Health Key Laboratory of Clinical Anesthesia, Department of Anesthesiology, Weifang Medical University, Weifang, China
Review Article
Sacubitril/valsartan: a new antihypertensive drug in the future?
Author(s): Guan Xuehao, Zhang Rui, Zhang Guangfang, Wang Jian, Wang Shuguang, Liu Baoshan* and Zhang Aiyuan*
Hypertension is one of the leading epidemic factors of cardiovascular and cerebrovascular disease around the
world. Many researchers have found that Sacubitril/Valsartan, the single angiotensin receptor-neprilysin inhibitor,
played a critical role in lowering hypertension. However, Sacubitril/Valsartan’s indications and usage for hypertension
has not been accepted in the world, except for China. The mechanism of Sacubitril/Valsartan’s antihypertensive
effect is clear, including inhibiting renin-angiotensin system and reducing natriuretic peptides’ degradation.
In this article, we retrieved and reviewed all clinical studies that explored the effect of Sacubitril/Valsartan or its
safety in the treatment of hypertension patients. Most studies concluded that in comparison with traditional
antihypertensive drugs (mainly including angiotensin receptor .. View More»